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INTRODUCTION
Peripheral blood progenitor cells (PBPC) have re p l a c e d
bone marrow as the pre f e rred source of stem cells because of
m o re rapid engraftment and possible improvement in malig-
nant contamination [1–3]. Current medical practice is to use
hematopoietic growth factors either alone or in combination
with chemotherapy to mobilize PBPC. The primary purpose
of this study was to determine if the combination of chemo-
therapy plus colony-stimulating factors—in this case,
cyclophosphamide, etoposide, and G-CSF—was better than
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ABSTRACT
Using matched-pair analysis, we compared two popular methods of stem cell mobilization in 24 advanced-stage
b reast cancer patients who underwent two consecutive mobilizing pro c e d u res as part of a tandem transplant pro t o-
col. For the first cycle, 10 mg/kg/day granulocyte colony-stimulating factor (G-CSF) was given and apheresis com-
menced on day 4 and continued for #5 days (median 3 days). One week after the first cycle of apheresis, 4000
m g / m2 cyclophosphamide, 400 mg/m2 etoposide, and 10 mg/kg G-CSF were administered for #16 days (cycle 2).
A p h e resis was initiated when the white blood cell (WBC) count exceeded 5000 cells/mL and continued for #5 days
(median 3 days). Mean values of peripheral blood WBC (31,700 6 3200 vs. 30,700 6 3 3 0 0 /mL) were not signifi-
cantly diff e rent between cycles 1 and 2. Mean number of mononuclear cells (MNC) collected per day was slightly
g reater with G-CSF mobilization than with the combination of chemotherapy and G-CSF (2.5 6 0 . 2 131 08 vs. 1.8 6
0 . 1 931 08 cells/kg). Mean daily CD341 cell yield, however, was nearly six times higher (12.9 6 4.4 vs. 2.2 6
0 . 531 06/kg; p 5 0.01) with chemotherapy plus G-CSF. With G-CSF alone, 13% of aphereses reached the targ e t
dose of 531 06 C D 3 41 cells/kg in one collection vs. 57% with chemotherapy plus G-CSF. Transfusions of red blood
cells or platelets were necessary in 18 of 24 patients in cycle 2. Three patients were hospitalized with fever for a
median of 3 days after cycle 2. No patients received transfusions or re q u i red hospitalization during mobilization
with G-CSF alone. Resource utilization (cost of drugs, aphereses, cry o p re s e rvation, transfusions, hospitalization)
was calculated comparing the median number of collections to obtain a target CD341 cell dose of 531 06 c e l l s / k g :
four using G-CSF vs. one using the combination in this data set. Resources for G-CSF mobilization cost $7326 vs.
$8693 for the combination, even though more apheresis pro c e d u res were perf o rmed using G-CSF mobilization.
The cost of chemotherapy administration, more doses of G-CSF, transfusions, and hospitalizations caused
cyclophosphamide, etoposide, and G-CSF to be more expensive than G-CSF alone. A less toxic and less expensive
t reatment than cyclophosphamide, etoposide, and G-CSF is needed to be more cost-effective than G-CSF alone for
peripheral blood progenitor cell mobilization.
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G-CSF alone to mobilize PBPC. A second purpose was to
c o m p a re re s o u rce utilization associated with these two
methods.
Our group has been evaluating models of consecutive or
tandem stem cell harvests and transplants for a number of
years [4–6]. We previously published a matched-pair analy-
sis for a series of stage IV breast cancer patients who under-
went two separate mobilizing treatments using combina-
tions of chemotherapy and hematopoietic growth factors. In
that study, we demonstrated that two consecutive courses of
cyclophosphamide, etoposide, and G-CSF led to progenitor
cell depletion following the second cycle of mobilizing
t reatment and that insufficient numbers of cells were col-
lected to support a second transplant using only the cells
collected from the second harvest [6]. In the current study,
we again perf o rmed matched-pair analysis of consecutive
breast cancer patients who were treated with two sequential
mobilizing treatments. The first treatment used G-CSF
alone beginning after full re c o v e ry from any prior chemo-
therapy, and the second used cyclophosphamide, etoposide,
and G-CSF after re t u rn of the white blood cell (WBC)
count to baseline after the first collection. Leukaphere s i s
was perf o rmed beginning on the 4th day of G-CSF tre a t-
ment and continued for up to 5 days during the first cycle.
During the second cycle, leukapheresis commenced when
WBC reached 5000/mm3 and continued for up to 5 days.
Each patient therefore served as a matched control for com-
parison of the two mobilizing methods. This study clearly
shows the superiority of the combination of chemotherapy
and G-CSF compared with G-CSF alone, with statistical
validity comparable to a prospective randomized study. This
s u p e r i o r i t y, however, did not translate into impro v e d
resource utilization during the mobilization procedure.
MATERIALS AND METHODS
Patient population
We studied 24 consecutive patients with stage III or IV
b reast cancer who were not eligible for interg roup bre a s t
cancer transplant protocols. Table 1 shows patient charac-
teristics. All met criteria for stem cell transplantation based
on hormone-insensitive disease; first chemotherapy tre a t-
ment for stage III or metastatic disease; and normal heart ,
lung, and renal function. Patients were enrolled from three
d i ff e rent treatment sites, and all patients gave written
informed consent for the protocol approved by the Institu-
tional Review Boards of Methodist, St. Vincent, and Com-
munity Hospitals in Indianapolis. Twenty of the 22 patients
with stage IV disease had prior adjuvant chemotherapy for
an initial stage II breast cancer and enrolled in this tre a t-
ment at the time of first relapse. All but one patient received
four to six cycles of standard chemotherapy for metastatic
b reast cancer before beginning the mobilizing tre a t m e n t
b e l o w. That one patient had locally re c u rrent disease that
was treated using irradiation and was not treated with addi-
tional chemotherapy at the time of relapse. 
Mobilizing tr e a t m e n t
B e f o re stem cell mobilization was attempted, patients
received several diff e rent chemotherapy regimens as induc-
tion therapy (patients with stage III disease) and to establish
chemosensitivity (patients with stage IV disease). Each re g i-
men was chosen by the re f e rring oncologist. All patients
then received two cycles of mobilizing treatment and leuka-
p h e resis after completing the initial phase of chemotherapy.
Cycle 1 of mobilizing treatment used 10 mg/kg G-CSF
administered subcutaneously once a day. G-CSF was starte d
21–31 days from the previous cycle of chemotherapy to
e n s u re that any mobilizing effect of the prior chemotherapy
was not a factor. Leukapheresis commenced on day 4 of
t reatment and continued for up to 5 days (median 3). Cycle
2 of mobilizing treatment was given as previously described
using 4000 mg/m2 cyclophosphamide over a 2-hour infu-
sion on day 1, 200 mg/m2 etoposide over a 2-hour infusion
on days 1 and 2, and 10 mg/kg G-CSF subcutaneously
once a day beginning on day 3 and continuing until the
final day of leukapheresis [6]. This second cycle began no
sooner than 7 days after the last day of leukapheresis of
cycle 1. Supportive care consisted of mesna for uro p ro p h y-
laxis and dexamethasone with intravenous ondansetron or
g r a n i s e t ron for emesis prevention. Leukapheresis was car-
ried out daily, starting when the peripheral blood count
had risen to at least 5000 per mm3, for up to 5 days. No
routine monitoring of peripheral blood CD341 cells was
d o n e .
L e u k ap h e re s i s
L e u k a p h e resis and cry o p re s e rvation were perf o rm e d
daily as previously described [6] using the Cobe Spectra
(Lakewood, CO). All patients had 2.5 to 3 blood volumes
p rocessed per day with flow rates between 60 and 120
mL/hour through central venous access (Quinton or Perm-
cath dialysis catheter). The collection procedure during the
first mobilization started on the 4th day of G-CSF. After the
second mobilizing procedure, the collection began when the
peripheral WBC exceeded 5000 cells/mm3. Cry o p re s e rv a-
tion was performed using a Cryomed controlled rate freezer
with 10% dimethylsulfoxide. Each product was stored in the
liquid phase of N2 until use. 
Quantification of progenitor cells
A sample of each day’s product was taken for the analy-
ses described, and the rest was cryopreserved. The samples
were routinely analyzed for leukocyte counts, white cell dif-
f e rential, colony-forming units-granulocyte-macro p h a g e
(CFU-GM), and CD341 cell assays. The total mononuclear
cells (MNC) were determined by excluding neutro p h i l s ,
bands, and eosinophils.
CFU-GM content was determined by plating total
leukocytes at a concentration of 105–106/mL in methylcellu-
lose and complete medium as previously described [6].
Table 1. Patient characteristics
n 24
Age (years)
Median 43
Range 33–58
Stage III disease 2
Stage IV disease 22
Prior chemotherapy 20
Known marrow involvement 0
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Colonies were enumerated on day 14 from duplicate plates;
mean values were reported. 
The CD341 cells were enumerated using a directly con-
jugated anti-CD34 antibody labeled with phycoery t h r i n
(Becton Dickinson) and analyzed on a FA C S t a rp l u s f l o w
cytometer (Becton Dickinson). Gating was performed either
a c c o rding to ISHAGE standards [7] or (prior to the 1997
publication of those standards) by previously described
methods [6]. 
R e s o u r ce utilization
Outpatient and inpatient re s o u rce utilization was deter-
mined based on the services perf o rmed and the complica-
tions of treatment. Mobilizing therapy was perf o rmed on
an outpatient basis, so the total charges assessed for the
outpatient services were collected and assigned the cost of
the services as 50% of charges. Blood products were tre a t e d
separately and assigned the costs of $300 per red cell unit
transfused and $800 per platelet product transfused. Inpa-
tient hospitalization for complications of treatment was
assigned the cost of $1500 per day based on published data
f rom MEDPAR [8]. Using these costs, it was possible to
d e t e rmine the re s o u rce utilization for each patient individ-
ually and for group as a whole.
R e s o u rce utilization by the 24 patients was separately
modeled to determine a cost for the mobilization treatment.
We developed three different models based on two different
methods of determining costs and two diff e rent endpoints
for apheresis. In models 1 and 3, we made cost calculations
based on discount of current outpatient charges as above.
Model 2 used costs as reported by Meisenberg et al. [9]. In
models 1 and 2, the costs associated with obtaining 53106
CD341 cells/kg using the mean daily CD341 cells collected
for each patient were calculated with no limit to the number
of aphereses. Model 3 limited the total number of aphereses
to five procedures per cycle. In these models, we purposely
omitted oral medications and routine laboratory tests such
as complete blood counts since these costs were small and
varied little between the two courses of mobilization. We
also did not include an accounting of indirect costs, which
w e re greater during the second cycle, which was adminis-
t e red over 13–16 days (the first cycle lasted 5–8 days).
Model 2 calculations were made based on average wholesale
price and the costs of apheresis as reported [9].
Statistical methods 
Sample size was determined by analysis for dependent
t testing using a power of 0.9, a standard deviation of 10,
and a difference in means of three times or more for CD34
results. The paired t test was used to compare parameters
between the first and second cycle of mobilization for data
with a normal distribution. The two-tailed Mann-Whitney
test was used to compare parameters when the data did not
have normal distribution. There was no randomization
re g a rding which mobilizing treatment was administere d
first, chemotherapy plus G-CSF or G-CSF alone, because
our previous data showed that chemotherapy plus G-CSF
can diminish the number of PBPC collected during a sec-
ond cycle of the same treatment [6], and we wanted to avoid
the likely possibility that the combination would negatively
affect the collection using G-CSF alone.
RESULTS
Patients and tr e a t m e n t s
Twenty-four patients, median age 45 (range 33–58),
u n d e rwent two cycles of mobilizing therapy. All had a mini-
mum of 2 days of collections with each cycle of tre a t m e n t .
The median number of days between the end of the first col-
lection after cycle 1 and the start of cycle 2 chemotherapy
was 9 (range 8–21). A median of 3 days of leukapheresis took
place during cycle 1 (range 2–5) and 4 days during cycle 2
(range 2–5). Cycle 2 leukapheresis commenced a median of
13 days (range 9–15) after starting cyclophosphamide. Four
of the 24 patients had a WBC count ,5000 at the start of
cycle 2 leukapheresis. The mean peripheral blood WBC dur-
ing cycle 1 was 31,700 6 3200 cells/mL, and during cycle 2,
30,700 6 3500 cells/mL (p 5 0.4). According to a pre d e t e r-
mined goal, the second collection was completed when there
w e re sufficient numbers of cells collected during both har-
vests to support two transplants. If patients mobilized poorly
during cycle 1, they were more likely to undergo 5 days of
l e u k a p h e resis during cycle 2 to ensure that sufficient PBPC
w e re collected to perf o rm two transplants. To ensure pro m p t
engraftment, at least 531 06 C D 3 41 cells were collected per
transplant (1031 06 total); six patients failed to meet this goal
after both cycles of collections. Four of the six underw e n t
p ro c e d u res to collect additional progenitors: three had bone
m a rrow harvests and one had an additional leukaphere s i s
cycle using the combination of G-CSF and granulocyte-
m a c rophage (GM)-CSF. All patients had prompt engraft-
ment following subsequent tandem transplants, and there
was no tre a t m e n t - related mortality (data not shown). 
When we began this study, we had anticipated perf o rm-
ing two transplant pro c e d u res for all patients, the first using
PBPC from the first mobilization with G-CSF alone and the
second using stem cells derived from the combination. This
strategy was anticipated to decrease the number of potential
contaminating malignant cells in the final product infused
during the second transplant. We knew from our prior studies
using the identical combination of chemotherapy and gro w t h
factors that the average daily collection contained .531 06
C D 3 41 cells/kg [6]. We reasoned that if G-CSF alone re s u l t-
ed in a similar product, we would be able to collect suffic i e n t
stem cells for two transplants in a reasonably small number
of collections, since another goal of this study was to perf o rm
as few apheresis pro c e d u res as possible. We there f o re limited
the total number of collections during the first cycle to fiv e
or fewer, assuming that, on average, the second collection
cycle could meet the total collection goal after 2 days. Any
patient who failed to have sufficient cells collected using G-C S F
alone would thus have needed to meet the goal for both
transplants by having the deficit collected during the second
cycle. While the study was ongoing, it was clear that many
patients were failing to reach the goal of 531 06 C D 3 41 c e l l s / k g
during the first cycle of mobilizing treatment with G-CSF
alone. There f o re, we abandoned the plan to infuse only
those cells obtained during the first collection during the
first transplant. Hence, it is not possible to compare the
engraftment kinetics following the two diff e rent transplants.
L e u k ap h e r esis pr o d u c t s
Table 2 shows the content of leukapheresis pro d u c t s
obtained using the two mobilizing regimens. The number of
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MNC per kilogram of patient weight was greater following
cycle 1, but the number of progenitor cells as measured by
either CFU-GM or CD341 cells was significantly higher with
cycle 2. The daily median number of CD341 cells/kg was
1 . 2 331 06 (range 0.2–7.6631 06) for cycle 1 and 5.6231 06
(range 0.48–88.831 06) for cycle 2. Four of the 24 patients
had poorer PBPC yields during the second cycle than the
first; all four had lower mean CD341 values than the group as
a whole, and three of the four had lower median CD341 v a l-
ues, suggesting that these patients had intrinsic factors caus-
ing poor mobilization. Ten patients had a mean of #1 . 031 06
C D 3 41 cells/kg for the cycle 1 daily collection; six of the 10
had CD341 cell yields during cycle 2 in excess of 2.531 06 p e r
d a y. Thus, even when fewer than average progenitors were
collected during cycle 1, the combination of chemotherapy
and G-CSF still was able to generate very good PBPC pro d-
ucts in most patients. For the group as a whole, there was a
5.8-fold higher yield using the combination of chemotherapy
and G-CSF compared with G-CSF alone.
Most transplant programs have adopted minimum
acceptable criteria for PBPC collections, usually based on the
total number of CD341 cells collected. Only seven of the
patients (29%) obtained a target of 231 06 C D 3 41 c e l l s / k g
with the first day of leukapheresis using G-CSF alone, while
16 (67%) achieved this level using the combination of chemo-
therapy and G-CSF. For a target of 531 06 C D 3 41 c e l l s / k g ,
the success rates of a single apheresis were 13 and 57%,
re s p e c t i v e l y. Eight patients failed to meet the target dose of
531 06 C D 3 41 cells/kg with the first cycle and three failed
with the second. 
R e s o u r ce utilization
R e s o u rce utilization for both mobilization methods is
recorded in Table 3. The initial mobilizing treatment using
G-CSF was generally well tolerated and did not require any
blood products, intravenous medications, or hospitalization.
Specific use of oral analgesics or oral antibiotics was not sep-
arately evaluated during either mobilization cycle. The
chemotherapy plus G-CSF mobilization cycle was associat-
ed with a frequent need for red cell or platelet transfusions.
Eighteen of the 24 patients (75%) re q u i red red cells,
platelets, or both. The indication for red cell transfusion was
the presence of symptomatic anemia with a hemoglobin
level ,8. The indication for platelet transfusion was a value
,20,000 on a day of apheresis or ,10,000 if no aphere s i s
was planned. Episodes of neutropenic fever occurred in
t h ree patients, all of whom were hospitalized and given
intravenous antibiotics. No documented infections were
identified. No patient failed to have leukapheresis per-
formed after the second mobilization treatment. 
Cost comparison
F rom the above data, we calculated the costs of mobi-
lizing treatment during cycles 1 and 2. Since no patient
needed blood products or hospitalization during cycle 1,
the costs of the G-CSF administration, apheresis, and cry-
o p re s e rvation re p resented the expenditures during that
cycle. The costs of cycle 2 included the chemotherapy
administration, G-CSF administration, hospitalization for
n e u t ropenic fever, blood products, apheresis, and cry o p-
re s e rvation. To generate a mean value for cycle 2, the costs
for blood products and hospitalization were totaled and
divided by 24. From the data above, the average number of
collections to reach the target goal of 531 06 C D 3 41
cells/kg was four for cycle one and one for cycle two. The
cost assigned to cycle 1 was $7326 and cycle 2, $8693.
We further explored this data set by evaluating thre e
different cost models. Table 4 shows cost modeling to obtain
a target goal of 531 06 C D 3 41 cells/kg. The cost calcula-
tions were performed on each patient during both cycles of
treatment and used the individual’s mean daily CD341 cell
number for that cycle to determine how many collections
that patient would need to obtain the target goal. The medi-
an number of collections was four (range one to 25) for
cycle 1 and two (range one to 10) for cycle 2. Method 1 in
this table calculated costs as described above, which used
50% of outpatient charges as being typical for expenditures
for this procedure. Model 2 followed the method and costs
Table 2. Compositions of collected leukapheresis products
Mean daily value Cycle 1 Cycle 2 p value
MNC 310 8/kg 2.5 6 0.21 1.8 6 0.19 0.0045
CFU-GM 310 4/kg 22.0 6 4.4 48.5 6 2.3 0.012
CD34 + cells 310 6/kg 2.2 6 0.50 12.9 6 4.41 0.016
Table 3. Resource utilization
Number of patients 
Cycle 1 Cycle 2
Red cell transfusions 0 13 (34 units)
Platelet transfusions 0 10 (21 units)
Fever .101° 0 3
Hospitalization 0 3
Table 4. Cost comparisons to achieve 53106 CD34+ cells/kg
Cycle 1 Cycle 2 p value
Method 1 $9504 6 1613 $11,135 6 982 0.20
Method 2 $14,079 6 2403 $13,635 6 1188 0.71
Method 3 $6864 6 500 $10,475 6 741 ,0.01
Method 1: Charges for cyclophosphamide ($102.85/1000 mg), VP-16
($273/100 mg), G-CSF ($573.80/480 µg), ondansetron ($384/32 mg),
IV fluids ($28/liter) , nursing administration ($150),  leukapheresis
($1100), and cryopreservation ($1100), all multiplied by 50%. Costs of
transfusions and hospitalizations as described in the text.
Method 2: Chemotherapy charges based on 1998 average wholesale prices.
Nursing time, apheresis, cryopreservation as published [9].
Method 3: Costs assigned as in method 1 but no more than five aphereses
performed during either cycle. Seven patients during cycle 1 and three dur-
ing cycle 2 would have failed to meet the goal of CD34+ cells during that col-
lection. Median number of collections to meet the goal was four (range one to
five) for cycle 1 and two (range one to five) for cycle 2.
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in Meisenberg’s analysis [9]. Since it is usually not feasible to
ask patients to undergo more than about five apheresis pro-
cedures during any planned collection, we also determined
the costs for each patient to obtain the goal of 531 06
C D 3 41 cells/kg during a maximum of five collections
(method 3). With this final method, seven patients would
have failed to meet the goal using G-CSF mobilization and
three would have failed to meet the goal during the combi-
nation. In these three models, the cost for cycle 1 ranged
from $6864 to $14,079 and for cycle 2, $10,475 to $13,635.
Only model 3 appeared to have a significant cost difference
between cycle 1 and 2 (favoring cycle 1). There was no cost
advantage to using the combination of cyclophosphamide,
etoposide, and G-CSF in this group of patients in any of the
models.
DISCUSSION
Our data show a nearly sixfold average increase in the
number of CD341 PBPC that can be mobilized from tre a t-
ment with 4000 mg/m2 cyclophosphamide, 400 mg/m2
etoposide, and 10 mg/kg/day G-CSF compared with G-CSF
alone. The optimal method to mobilize and collect PBPC
remains to be defined. This re p o rt is one of very few that
have directly compared one method of mobilization with
another and demonstrates improved CD341 cell mobiliza-
tion using chemotherapy plus a cytokine vs. using a cytokine
alone. Available data strongly support the conclusion that
PBPC infusions containing .531 06 C D 3 41 cells/kg are
associated with more rapid engraftment and less graft failure
[13–17]. Table 5 summarizes recently published data for the
quantity of CD341 cells collected per day using several dif-
f e rent methods of PBPC mobilization. These publications
w e re chosen because one method was compared with at least
one other method, mostly using consecutive groups of
patients rather than randomized groups. No definite conclu-
sions can be drawn from this compilation of results, but
i m p o rtant trends might guide current clinical practice. First,
most methods appear adequate to reach a target goal of
531 06 C D 3 41 cells/kg for patients who have not been heavi-
ly pre t reated, but five collections may be re q u i red in some
patients. Second, the highest numbers of CD341 cells are
found using combinations of more than one cytokine or
chemotherapy plus cytokines. How important chemotherapy
is to eliminate potential contaminating tumor cells in the
stem cell product cannot be answered by the re f e re n c e d
Table 5. Comparison of PBPC mobilization methods
Daily number % of patients % of patients
Patient Mobilization method* CD34 1 cells who did not who met goal
population (number of patients) (310 6/kg) † meet goal ‡ in one collection ‡ Reference
Breast cancer Cytoxan 1.5 g/m 2 1 GM-CSF 5 mg/kg 3 5d 4.5 0§ 66 § [9]
1 G-CSF 10 mg/kg (35)
G-CSF 10 mg/kg (21) 1.8 10 § 14 §
Myeloma Cytoxan 4 g/m 2 1 GM-CSF 8 mg/kg (18) 1.98 NA NA [10]
G-CSF 10 mg/kg (22) 1.05 NA NA
Myeloma Cytoxan 6g/m 2 1 G-CSF 5 mg/kg (22) 4.8 18 § NA [11]
G-CSF 16 mg/kg (22) 1.2 24 § NA
Breast cancer Cytoxan 4 g/m 2 1 VP-16 600 mg/m 2 11.1 6 70 [12]
1 G-CSF 6 mg/kg (156)
Cytoxan 2 g/m 2 1 VP-16 600 mg/m 2 9.9 4 72
1 G-CSF 6 mg/kg (162)
Breast cancer Cytoxan 4 g/m 2 1 paclitaxel 170 mg/m 2 12.9 0 NA [18]
1 G-CSF 10 mg/kg (58)
Cytoxan 4 g/m 2 1 VP-16 600 mg/m 2 11.0 0 NA
1 G-CSF 10 mg/kg (13)
Cytoxan 4 g/m 2 1 G-CSF 16 mg/kg (10) 2.0 30 NA
Breast cancer G-CSF 10 mg/kg 1 SCF 250 mg/m 2 (59) 2.6 40 NA [19]
G-CSF 10 mg/kg (41) 1.1 67 NA
Breast cancer G-CSF 10 mg/kg continuous SQ 8.2 NA NA [20]
(untreated) 1 SCF 10 mg/kg (11)
G-CSF 12 mg/kg continuous SQ (18) 3.8 NA NA
Breast cancer G-CSF 30 mg/kg (14) 2.4 29 29 [21]
G-CSF 10 mg/kg (14) 0.6 86 0
Breast cancer Daniplestim 2.5 mg/kg 3.6 50 § NA [22]
1 G-CSF 10 mg/kg (6)
G-CSF 10 mg/kg (16) 2.1 83 § NA
Breast cancer Cytoxan 4 g/m 2 1 VP-16 400 mg/m 2 12.9 13 57 Current study
1 G-CSF 10 mg/kg (24)
G-CSF 10 mg/kg (24) 2.2 33 13
*G-CSF, GM-CSF, and SCF given daily subcutaneously until the completion of apheresis unless otherwise specified.
†Median values.
‡Goal of 53106 CD 341 cells/kg unless marked by §43106 CD 341 cells/kg.
NA, not assessed in report.
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studies. Third, it is possible to obtain the target goal of
.531 06 C D 3 41 cells/kg in most breast cancer patients with
just one leukapheresis pro c e d u re using the combination of
chemotherapy and cytokines. Fourth, a small group of
patients cannot be adequately mobilized with any of the
methods listed; second-line strategies for these patients con-
tinue to be needed. 
The data are surprisingly consistent from one group to
another as to the quantity of CD341 cells mobilized using
the daily single-dose administration of 10 mg/kg G-CSF
alone (0.6–2.2 CD341 cells 31 06/kg). For most patients
receiving only 10 mg/kg/day G-CSF subcutaneously, two or
m o re apheresis pro c e d u res will be necessary to reach the
t a rget goal as described. To improve on these results, it will
be necessary to find better combinations of chemotherapy,
better combinations of the currently available cytokines,
better dosing schedules such as two or three administra-
tions per day, or more effective agents to mobilize stem
cells. 
Cost considerations cannot be disre g a rded when com-
paring one method of PBPC mobilization with another. We
had anticipated that the increased resources used during the
administration of chemotherapy would be more than offset
by the decreased use of resources during apheresis and cry-
o p re s e rvation. However, the increased number of transfu-
sions and need for hospitalizations for neutropenic fever off-
set the potential cost savings for this strategy. The benefit of
fewer numbers of apheresis during the combination of
chemotherapy and G-CSF was at the cost of added toxicity
and resource utilization. 
T h ree recent studies reach diff e rent conclusions when
comparing mobilization with cyclophosphamide and G-
CSF (or GM-CSF) vs. G-CSF alone [9–11]. Both a non-
randomized study [10] and a randomized study [11] in
multiple myeloma patients showed enhancement of the
number of CD341 cells collected by the combination com-
p a red with the cytokine alone. Both also concluded that
the increased toxicity with the combination was not off s e t
by chemotherapy-induced enhancement of pro g e n i t o r s ,
since most patients were able to meet preestablished goals
for harvesting using G-CSF alone. Neither study looked at
costs specifically, but both evaluated certain categories of
re s o u rce utilization. The two studies demonstrated that
engraftment following transplantation was the same
re g a rdless of the method used to mobilize stem cells. Our
data draw similar conclusions in a diff e rent patient popula-
tion (advanced breast cancer) but offer more detailed cost
analysis. In both of the myeloma studies, 100% of the
patients re q u i red hospitalization during chemotherapy plus
G-CSF mobilization, shifting the cost advantage consider-
ably in favor of G-CSF alone. In our study, however, even
when only 13% of patients were hospitalized for a total of
9 days, there still was no clear cost advantage for the tre a t-
ment that produced higher numbers of circulating pro-
genitor cells. 
M e i s e n b e rg came to diff e rent conclusions in a cohort
study of 56 stage II–IV breast cancer patients receiving 1500
m g / m2 cyclophosphamide combined with 250 mg / m2 G M -
CSF on days 3–5 and 10 mg/kg G-CSF on days 6–11 com-
pared with the same dose of G-CSF alone [9]. The number
of patients who developed toxicity or re q u i red hospitaliza-
tion during the cycle of chemotherapy and cytokines
a p p e a red to be significantly less than in our re p o rt. Only
one patient required hospitalization, and no patient required
red cell or platelet transfusions. The combination of
cyclophosphamide and cytokines was cost-effective when
compared with G-CSF alone in Meisenberg’s study.
The most effective cyclophosphamide dose for stem cell
mobilization was addressed by a recent study that compared
2000 and 4000 mg/m2 cyclophosphamide in combination
with 600 mg/m2 etoposide and 6 mg/kg/day G-CSF [12].
The number of CD341 cells collected was the same for both
doses, as was engraftment following transplant, but the fre-
quency of complications including hospitalization, mucosi-
tis, nausea, vomiting, and red cell and platelet transfusions
was greater at the higher dose. While our study diff e re d
f rom these two studies in the dose of either cyclophos-
phamide or etoposide, a clear conclusion is that a decreased
dose of cyclophosphamide is associated with less toxicity.
Our results in a breast cancer population are similar to
the results in two myeloma populations [10,11], in which
doses of cyclophosphamide were at least 4000 mg/m2. Our
results differ from Meisenberg [9] who used a lower dose
of cyclophosphamide (1500 mg/m2) but had a slightly
lower goal of harvested CD341 cells (431 06 cells/kg). Our
data suggest that the cost of mobilization using combina-
tion chemotherapy and G-CSF in the dose of 10 mg / k g / d
has a minimum expense of about $8500, including ~$7000
for the administration of the chemotherapy, antiemetics,
G - C S F, and management of complications, plus a cost of
~$1500 per extra day of leukapheresis. Indirect costs and
patient expenses are additional considerations. The com-
plications that occurred during the combination tre a t m e n t
resulted in ~$2000 per patient when averaged over the
e n t i re patient group, a figure dramatically diff e rent fro m
M e i s e n b e rg ’s data, which showed complications averaging
$224. The minimum expense of administering just G-CSF
and perf o rming a single apheresis is about $2750, $1250
for the G-CSF administration and monitoring and $1500
for leukapheresis. 
Potential opportunities to obtain cost savings from our
methods include decreasing the dose of cyclophosphamide,
eliminating VP-16 from the program, omitting the use of
mesna as a urothelial protectant, and using less G-CSF by
either giving a lower daily dose or starting it later. Data
f rom Table 5 suggest that decreasing the dose of cyclophos-
phamide would provide similar numbers of CD341 cells as
well as decrease associated toxicity. The elimination of
etoposide would likely decrease the number of pro g e n i t o r s
collected, resulting in an increase in the number of collec-
tions re q u i red to obtain the target goal. This may or may
not be a cost-effective strategy. Decreasing the toxicity
would allow the combination of chemotherapy and G-CSF
to be more cost-effective than G-CSF alone. 
As newer agents become available that enhance PBPC
mobilization compared with G-CSF or GM-CSF alone,
simple cost calculations can guide whether the expense of
the new agent is balanced by the elimination of the expense
of the apheresis procedure, which costs about $1500 per day.
If the newer agent has a cost similar to G-CSF or GM-CSF
and is used in combination with one of those drugs at simi-
lar doses, the expense of using the cytokine combination is
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doubled compared with either G-CSF or GM-CSF alone.
The above cost data would suggest that this impro v e m e n t
will be cost-effective only if it decreases the number of
apheresis procedures by more than half. The initial reports
using either stem cell factor or daniplestim [19,20,22] sug-
gest that doubling the number of PBPC mobilized (and
t h e reby halving the number of apheresis pro c e d u res) may
not be accomplished with these agents, but further studies
are needed.
In summary, the combination of cyclophosphamide,
VP-16, and G-CSF enhances the number of PBPC mobi-
lized by more than fivefold compared with G-CSF alone,
but this enhancement was offset by increased toxicity, result-
ing in considerable costs for the combination.
REFERENCES
1 To LB, Haylock DN, Simmons PJ, Juttner CA: The biology and clin-
ical use of blood stem cells. Blood 89:2333, 1997.
2 Gillespie TW, Hillyer CD: Peripheral blood progenitor cells for
marrow reconstitution: mobilization and collection strategies. Transfu-
sion 36:611, 1996.
3 Ross AA: Minimal residual disease in solid tumor malignancies: a
review. J Hematother 7:9, 1998.
4 Nichols CR, Tricot G, Williams SD, Van Besien K, Loehrer PJ, Roth
BJ, Akard L, Hoffman R, Goulet R, Wolff SN, Giannone L, Greer J, Ein -
horn L, Jansen J: Dose intensive chemotherapy in refractory germ cell
cancer: a phase I/II trial of high-dose carboplatin and etoposide with
autologous bone marrow transplantation. J Clin Oncol 7:932, 1989.
5 Van Besien K, Nichols CR, Tricot G, Langefeld C, Miller ME, Akard
LP, English DK, Graves VL, Cheerva A, McCarthy LJ, Jansen J: Charac-
teristics of engraftment after repeated autologous bone marrow trans-
plantation. Exp Hematol 18:785, 1990.
6 Akard LP, Wiemann M, Thompson JM, Swinney M, Lynn K, Hanks
S, Jansen J: Impaired stem cell collection by consecutive courses of
high-dose mobilizing chemotherapy using cyclophosphamide, etopo-
side, and G-CSF. J Hematother 5:271, 1996.
7 Sutherland DR, Anderson L, Keeney M, Nayar R, Chin-Yee I: T h e
ISHAGE guidelines for CD341 cell determination by flow cytometry. J
Hematother 5:213, 1996.
8 Department of Health and Human Services Health Care Financing
Administration: Medicare Provider Analysis and Review (MEDPAR),
1996.
9 Meisenberg B, Brehm T, Schmeckel A, Miller W, McMillan R: A com-
bination of low-dose cyclophosphamide and colony-stimulating factors
is more cost effective than granulocyte-colony-stimulating factors alone
in mobilizing peripheral blood stem and progenitor cells. Transfusion
38:209, 1998.
10 Alegre A, Tomas JF, Martinez-Chamorro C, Gil-Fernandez JJ, Fer -
nandez-Villalta MJ, Arranz R, Diaz MA, Granda A, Bernardo MR, Escud -
ero A, Lopez-Lorenzo JL: Comparison of peripheral blood progenitor
cell mobilization in patients with multiple myeloma: high dose
cyclophosphamide plus GM-CSF vs G-CSF alone. Bone Marrow
Transplant 20:211, 1997.
11 Desikan KR, Barlogie B, Jagannath S, Vesole DH, Siegel D, Fassas A,
Munshi N, Singhal S, Mehta J, Tindle S, Nelson J, Bracy D, Mattox S,
T r icot G : Comparable engraftment kinetics following peripheral-blood
stem-cell infusion mobilized with granulocyte colony stimulating factor
with or without cyclophosphamide in multiple myeloma. J Clin Oncol
16:1547, 1998.
12 Schwartzberg LS, Weaver CH, Birch R, Manner C, Tauer K, Beeker
T, Morgan-Ihrig C, MacAneny B, Leff R, Smith R, Hainsworth J, Greco T,
Schwerkoske J, Murphy MN, Buckner CD: A randomized trial of two
doses of cyclophosphamide with etoposide and G-CSF for mobilization
of peripheral blood stem cells in 318 patients with stage II-III breast
cancer. J Hematother 7:141, 1998.
13 Van der Wall E, Richel DJ, Holtkamp MJ, Baars JW, Schornagel JH,
Peterse JL, Beijnen JH, Rodenhuis S: Bone marrow reconstitution after
high-dose chemotherapy and autologous peripheral blood progenitor
cell transplantation: effect of graft size. Ann Oncol 5:795, 1994.
14 Weaver, CH, Hazelton B, Birch R, Palmer P, Allen C, Schwartzberg L,
West W: An analysis of engraftment kinetics as a function of the CD34
content of peripheral blood progenitor cell collections in 692 patients
after the administration of myeloablative chemotherapy. Blood
86:3961, 1995.
15 Dercksen MW, Rodenhuis S, Dirkson MK, Schaasberg WP, Baars JW,
Van der Wall E, Slapper-Cortenbach IC, Pinedo HM, Von dem Borne AE,
Van der Schoot CE: Subsets of CD341 cells and rapid hematopoietic
recovery after peripheral-blood stem-cell transplantation. J Clin Oncol
13:1922, 1995.
16 Kiss JE, Rybka WB, Winkelstein A, deMagalhaes-Silverman M, Lister
J, D’Andrea P, Ball ED: Relationship of CD341 cell dose to early and
late hematopoiesis following autologous peripheral blood stem cell
transplantation. Bone Marrow Transplant 19:303, 1997.
17 Shpall EJ, Champlin R, Glaspy JA: Effect of CD341 p e r i p h e r a l
blood progenitor cell dose on hematopoietic recovery. Biol Blood Mar-
row Transplant 4:84, 1998.
18 Demirer T, Buckner CD, Storer B, Lilleby K, Rowley S, Clift R, Appel -
baum FR, Storb R, Bensinger WI: Effect of different chemotherapy regi-
mens on peripheral-blood stem-cell collections in patients with breast
cancer receiving granulocyte colony-stimulating factor. J Clin Oncol
15:684, 1997.
19 Glaspy JA, Shpall EJ, LeMaistre CF, Briddell RA, Menchaca DM,
Turner SA, Lill M, Chap L, Jones R, Wiers MD, Sheridan WP, McNiece
IK: Peripheral blood progenitor cell mobilization using stem cell factor
in combination with filgrastim in breast cancer patients. Blood 90:2939,
1997.
20 Basser RL, To LB, Begley CG, Maher D, Juttner C, Ceborn J, Mans -
field R, Olver I, Duggan G, Szer J, Collins J, Schwartz B, Marty J, Men -
chaca D, Sheridan WP, Fox RM, Green MD: Rapid hematopoietic recov-
ery after multicycle high-dose chemotherapy: enhancement of fil g r a s-
tim-induced progenitor-cell mobilization by recombinant human stem-
cell factor. J Clin Oncol 16:1899, 1998.
2 1 Weaver CH, Birch R, Greco FA, Schwartzberg L, McAneny B, Moore M,
Oviatt D, Redmond J, George C, Alberico T, Johnson P, Buckner CD: M o b i-
lization and harvesting of peripheral blood stem cells: randomized evalu-
ations of different doses of filgrastim. Br J Haematol 100:338, 1998.
22 DiPersio JF, Abboud CN, Schuster MW, Winter JN, Collins DM,
Santos VR, Baum CM: Phase II study of mobilization of PBSC by
administration of daniplestim (SC-55494) and G-CSF in patients with
breast cancer or lymphoma. Proc Annu Meet Am Soc Clin Oncol
16:A306, 1997.
